

## Datasheet: MCA519GT

**BATCH NUMBER 168864**

|                      |                                      |
|----------------------|--------------------------------------|
| <b>Description:</b>  | RAT ANTI MOUSE MACROPHAGES/MONOCYTES |
| <b>Specificity:</b>  | MACROPHAGES/MONOCYTES                |
| <b>Format:</b>       | Purified                             |
| <b>Product Type:</b> | Monoclonal Antibody                  |
| <b>Clone:</b>        | MOMA-2                               |
| <b>Isotype:</b>      | IgG2b                                |
| <b>Quantity:</b>     | 25 µg                                |

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

|                            | Yes | No | Not Determined | Suggested Dilution |
|----------------------------|-----|----|----------------|--------------------|
| Flow Cytometry (1)         | ▪   |    |                |                    |
| Immunohistology - Frozen   | ▪   |    |                | 1/25               |
| Immunohistology - Paraffin |     |    | ▪              |                    |
| ELISA                      |     |    | ▪              |                    |
| Immunoprecipitation        |     |    | ▪              |                    |
| Western Blotting           |     |    | ▪              |                    |
| Immunofluorescence         | ▪   |    |                |                    |

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

**(1) Membrane permeabilization is required for this application. The use of Leucoperm (Product Code [BUF09](#)) is recommended for this purpose.**

|                        |  |
|------------------------|--|
| <b>Target Species</b>  | Mouse  |
| <b>Product Form</b>    | Purified IgG - liquid  |
| <b>Preparation</b>     | Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant. |
| <b>Buffer Solution</b> | Phosphate buffered saline.   |
| <b>Preservative</b>    | <0.1% Sodium Azide (NaN <sub>3</sub> ).  |

## Stabilisers

---

**Approx. Protein Concentrations** IgG concentration 0.5 mg/ml.

---

**Immunogen** Mouse lymph node stroma.

---

**RRID** AB\_1102752

---

**Fusion Partners** Spleen cells from immunized Wistar rats were fused with cells of the SP/0 myeloma cell line.

---

**Specificity** **Rat anti Mouse Macrophages/Monocytes antibody, clone MOMA-2** recognizes an intracellular antigen of mouse macrophages and monocytes. It reacts strongly with macrophages in lymphoid organs such as tingible body macrophages and macrophages in T cell dependant areas and is extremely useful in immunohistochemistry. Reacts on all mouse strains tested.

---

**Flow Cytometry** Use 10ul of the suggested working dilution to label  $1 \times 10^6$  cells in 100ul.

---

## References

1. Gal, A. *et al.* (1996) Nitric oxide production in SJL mice bearing the RcsX lymphoma: a model for in vivo toxicological evaluation of NO. [Proc Natl Acad Sci U S A. 93 \(21\): 11499-503.](#)
2. Dieleman, L.A. *et al.* (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. [Clin Exp Immunol. 114: 385-91.](#)
3. Fischer, M.B. *et al.* (1998) Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. [J Immunol. 160: 2619-25.](#)
4. Jiang, H.R. *et al.* (1999) Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. [Invest Ophthalmol Vis Sci. 40: 3177-85.](#)
5. Babaei, S. *et al.* (2000) Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation. [Cardiovasc Res. 2000 Oct;48: 158-67.](#)
6. Oguchi, S. *et al.* (2000) Monoclonal antibody against vascular cell adhesion molecule-1 inhibits neointimal formation after periadventitial carotid artery injury in genetically hypercholesterolemic mice. [Arterioscler Thromb Vasc Biol. 20: 1729-36.](#)
7. Kusunoki, J. *et al.* (2001) Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. [Circulation. 103: 2604-9.](#)
8. Lesnik, P. *et al.* (2003) Decreased atherosclerosis in CX3CR1<sup>-/-</sup> mice reveals a role for fractalkine in atherogenesis. [J Clin Invest. 111: 333-40.](#)
9. Oguro, A. *et al.* (2003) NaF induces early differentiation of murine bone marrow cells along the granulocytic pathway but not the monocytic or preosteoclastic pathway *in vitro*. [In Vitro Cell Dev Biol Anim. 39 \(5-6\): 243-8.](#)
10. Yun, J.J. *et al.* (2004) Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection. [Circulation. 109: 932-7.](#)
11. Addison, C.L. *et al.* (2004) Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. [BMC Cancer. 4: 28.](#)

12. Nakai, Y. *et al.* (2004) Natural killer T cells accelerate atherogenesis in mice. [Blood. 104 \(7\): 2051-9.](#)
13. Persson, L. *et al.* (2005) Immunoglobulin treatment reduces atherosclerosis in apolipoprotein E<sup>-/-</sup> low-density lipoprotein receptor<sup>-/-</sup> mice via the complement system. [Clin Exp Immunol. 142: 441-5.](#)
14. Wang, H. *et al.* (2006) Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. [J Clin Invest. 116: 2105-14.](#)
15. Bourdillon, M.C. *et al.* (2006) Reduced atherosclerotic lesion size in P-selectin deficient apolipoprotein E-knockout mice fed a chow but not a fat diet. [J Biomed Biotechnol. 2006 \(2\): 49193.](#)
16. Bhatia, V.K. *et al.* (2007) Complement C1q reduces early atherosclerosis in low-density lipoprotein receptor-deficient mice. [Am J Pathol. 170: 416-26.](#)
17. Nix, R.N. *et al.* (2007) Hemophagocytic macrophages harbor *Salmonella enterica* during persistent infection. [PLoS Pathog. 3\(12\):e193.](#)
18. Wang, Z. *et al.* (2008) Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. [J Clin Invest. 118: 195-204.](#)
19. Westmuckett, A.D. *et al.* (2009) Lack of tyrosylprotein sulfotransferase activity in hematopoietic cells drastically attenuates atherosclerosis in Ldlr<sup>-/-</sup> mice. [Arterioscler Thromb Vasc Biol. 29: 1730-6.](#)
20. Leung, V.W. *et al.* (2009) Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice. [Am J Pathol. 175: 1757-67.](#)
21. Yuan, Z. *et al.* (2009) Quantitative trait locus analysis of neointimal formation in an intercross between C57BL/6 and C3H/HeJ apolipoprotein E-deficient mice. [Circ Cardiovasc Genet. 2: 220-8.](#)
22. Pillai, M.M. *et al.* (2009) Inducible transgenes under the control of the hCD68 promoter identifies mouse macrophages with a distribution that differs from the F4/80 - and CSF-1R-expressing populations. [Exp Hematol. 37: 1387-92.](#)
23. Pedersen, T.X. *et al.* (2010) The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE<sup>-/-</sup> mice. [Nephrol Dial Transplant. 25: 2486-91.](#)
24. Chen, S. (2010) IL-17A is proatherogenic in high-fat diet-induced and *Chlamydia pneumoniae* infection-accelerated atherosclerosis in mice. [J Immunol. 185: 5619-27.](#)
25. Gao, Q. *et al.* (2010) A critical function of Th17 proinflammatory cells in the development of atherosclerotic plaque in mice. [J Immunol. 185: 5820-7.](#)
26. Madrigal-Matute, J. *et al.* (2010) Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis. [Cardiovasc Res. 86 \(2\): 330-7.](#)
27. Duewell, P. *et al.* (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. [Nature. 464: 1357-61.](#)
28. Li, J. *et al.* (2011) Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of {beta}-catenin signaling. [Mol Cell Biol. 31: 1134-44.](#)
29. Skoura, A. *et al.* (2011) Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. [Arterioscler Thromb Vasc Biol. 31 \(1\): 81-5.](#)
30. Frossard, J.L. *et al.* (2011) Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced

- acute pancreatitis and pancreatitis-associated lung injury. [J Clin Pathol. 64 \(5\): 387-93.](#)
31. de Jager, S.C. *et al.* (2011) Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis. [J Exp Med. 208 \(2\): 217-25.](#)
32. Ng, H.P. *et al.* (2011) Attenuated atherosclerotic lesions in apoE-Fcy-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 cells and promotion of regulatory T cells. [J Immunol. 187 \(11\): 6082-93.](#)
33. Weingärtner, O. *et al.* (2011) Differential effects on inhibition of cholesterol absorption by plant stanol and plant sterol esters in apoE<sup>-/-</sup> mice. [Cardiovasc Res. 90: 484-92.](#)
34. Yamamoto, S. *et al.* (2011) Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. [Nephrol Dial Transplant. 26 \(8\): 2491-7.](#)
35. Che, J. *et al.* (2011) Endothelial FGF receptor signaling accelerates atherosclerosis. [Am J Physiol Heart Circ Physiol. 300: H154-61.](#)
36. Ruf, M.T. *et al.* (2012) Chemotherapy-Associated Changes of Histopathological Features of *Mycobacterium ulcerans* Lesions in a Buruli Ulcer Mouse Model. [Antimicrob Agents Chemother. 56: 687-96.](#)
37. van der Sluis, R.J. *et al.* (2014) Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility. [J Endocrinol. 222 \(3\): 341-50.](#)
38. Lee, M.R. *et al.* (2014) The adipokine Retnla modulates cholesterol homeostasis in hyperlipidemic mice. [Nat Commun. 5: 4410.](#)
39. Song, G. *et al.* (2015) Molecular hydrogen stabilizes atherosclerotic plaque in low-density lipoprotein receptor-knockout mice. [Free Radic Biol Med. 87: 58-68.](#)
40. Shuto, Y. *et al.* (2015) Repetitive Glucose Spikes Accelerate Atherosclerotic Lesion Formation in C57BL/6 Mice. [PLoS One. 10 \(8\): e0136840.](#)
41. Takata, H. *et al.* (2015) Vascular angiotensin II type 2 receptor attenuates atherosclerosis via a kinin/NO-dependent mechanism. [J Renin Angiotensin Aldosterone Syst. 16 \(2\): 311-20.](#)
42. van der Sluis, R.J. *et al.* (2015) Haloperidol inhibits the development of atherosclerotic lesions in LDL receptor knockout mice. [Br J Pharmacol. 172 \(9\): 2397-405.](#)
43. Wan W *et al.* (2015) Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice. [Cardiovasc Res. 106 \(3\): 478-87.](#)
44. Oguiza A *et al.* (2015) Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes. [Diabetologia. 58 \(7\): 1656-67.](#)
45. Yamamoto, S. *et al.* (2015) Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype [Atherosclerosis. 242 \(1\): 56-64.](#)
46. Krishack, P.A. *et al.* (2015) Serum Amyloid A Facilitates Early Lesion Development in Ldlr<sup>-/-</sup> Mice. [J Am Heart Assoc. 4 \(7\): pii: e001858.](#)
47. Aoki, S. *et al.* (2015) Oral administration of the β-glucan produced by *Aureobasidium pullulans* ameliorates development of atherosclerosis in apolipoprotein E deficient mice [Journal of Functional Foods. 18: 22-7.](#)
48. Peng, Y. *et al.* (2016) Inactivation of Semicarbazide-Sensitive Amine Oxidase Stabilizes the Established Atherosclerotic Lesions via Inducing the Phenotypic Switch of Smooth Muscle Cells. [PLoS One. 11 \(4\): e0152758.](#)
49. Grootaert, M.O. *et al.* (2016) NecroX-7 reduces necrotic core formation in atherosclerotic plaques of Apoe knockout mice. [Atherosclerosis. 252: 166-74.](#)

50. Hong, Y.F. *et al.* (2016) *Lactobacillus acidophilus* K301 Inhibits Atherogenesis via Induction of 24 (S), 25-Epoxycholesterol-Mediated ABCA1 and ABCG1 Production and Cholesterol Efflux in Macrophages. [PLoS One. 11 \(4\): e0154302.](#)
51. Bosteen, M.H. *et al.* (2017) Effects of apolipoprotein M in uremic atherosclerosis. [Atherosclerosis. 265: 93-101.](#)
52. Neele, A.E. *et al.* (2018) Myeloid Kdm6b deficiency results in advanced atherosclerosis. [Atherosclerosis. 275: 156-65.](#)
53. Luque-Martin, R. *et al.* (2019) Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis. [Front Pharmacol. 10: 1242.](#)
54. Sun, Y. *et al.* (2019) Silencing of junctional adhesion molecule-like protein attenuates atherogenesis and enhances plaque stability in ApoE<sup>-/-</sup> mice. [Clin Sci \(Lond\). 133 \(11\): 1215-28.](#)
55. Tang, G. *et al.* (2019) Metformin inhibited Nod-like receptor protein 3 inflammasomes activation and suppressed diabetes-accelerated atherosclerosis in apoE<sup>-/-</sup> mice. [Biomed Pharmacother. 119: 109410.](#)
56. van Duijn, J. *et al.* (2019) CD8<sup>+</sup> T-cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4<sup>+</sup> T-cell responses. [Cardiovasc Res. 115 \(4\): 729-38.](#)
57. Zhao, J. *et al.* (2019) Atherogenesis in the Carotid Artery with and without Interrupted Blood Flow of Two Hyperlipidemic Mouse Strains. [J Vasc Res. 56 \(5\): 241-254.](#)
58. Burris, R.L. *et al.* (2020) Maternal exposure to soy diet reduces atheroma in hyperlipidemic F1 offspring mice by promoting macrophage and T cell anti-inflammatory responses. [Atherosclerosis. 313: 26-34.](#)
59. Baardman, J. *et al.* (2020) Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques. [Nat Commun. 11 \(1\): 6296.](#)
60. Kato, T. *et al.* (2020) A non-selective endothelin receptor antagonist bosentan modulates kinetics of bone marrow-derived cells in ameliorating pulmonary hypertension in mice. [Pulm Circ. 10 \(2\): 2045894020919355.](#)
61. Douna, H. *et al.* (2020) B- and T-lymphocyte attenuator stimulation protects against atherosclerosis by regulating follicular B cells. [Cardiovasc Res. 116 \(2\): 295-305.](#)
62. Gajeton, J. *et al.* (2020) miR-467 Prevents Inflammation And Insulin Resistance In Response To Hyperglycemia [BioRxiv. Jun 11 Preprint \[Epub ahead of print\].](#)
63. Lecoeur, H. *et al.* (2020) Targeting Macrophage Histone H3 Modification as a Leishmania Strategy to Dampen the NF-κB/NLRP3-Mediated Inflammatory Response. [Cell Rep. 30 \(6\): 1870-1882.e4.](#)
64. Gajeton, J. *et al.* (2021) Hyperglycemia-Induced miR-467 Drives Tumor Inflammation and Growth in Breast Cancer. [Cancers \(Basel\). 13 \(6\): 1346.](#)
65. Zhao, J. *et al.* (2021) Inflammation and enhanced atherogenesis in the carotid artery with altered blood flow in an atherosclerosis-resistant mouse strain. [Physiol Rep. 9 \(11\): e14829.](#)
66. Zhao, Y. *et al.* (2022) Specific Loss of ABCA1 (ATP-Binding Cassette Transporter A1) Suppresses TCR (T-Cell Receptor) Signaling and Provides Protection Against Atherosclerosis. [Arterioscler Thromb Vasc Biol. 42 \(12\): e311-e326.](#)
67. van Duijn, J. *et al.* (2021) Tc17 CD8<sup>+</sup> T cells accumulate in murine atherosclerotic lesions, but do not contribute to early atherosclerosis development. [Cardiovasc Res. 117 \(14\): 2755-66.](#)

68. Imai, T. *et al.* (2022) Smooth muscle cell specific NEMO deficiency inhibits atherosclerosis in ApoE<sup>-/-</sup> mice. [Sci Rep. 12 \(1\): 12538.](#)
69. Smit, V. *et al.* (2023) Single-cell profiling reveals age-associated immunity in atherosclerosis. [Cardiovasc Res. 119 \(15\): 2508-21.](#)
70. Karasawa, T. *et al.* (2023) Caspase-11 deficiency attenuates neutrophil recruitment into the atherosclerotic lesion in apolipoprotein E-deficient mice. [Biochem Biophys Res Commun. 686: 149158.](#)
71. Segers, F.M.E. *et al.* (2023) Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis. [Cardiovasc Res. 118 \(17\): 3346-59.](#)
72. Grievink, H.W. *et al.* (2021) Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. [Front Cardiovasc Med. 8: 740531.](#)
73. Douna, H. *et al.* (2022) IFN $\gamma$ -Stimulated B Cells Inhibit T Follicular Helper Cells and Protect Against Atherosclerosis. [Front Cardiovasc Med. 9: 781436.](#)
74. Smit, V. *et al.* (2024) Sexual dimorphism in atherosclerotic plaques of aged Ldlr(-/-) mice. [Immun Ageing. 21 \(1\): 27.](#)

---

**Storage** This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

**Guarantee** 12 months from date of despatch.

---

**Health And Safety Information** Material Safety Datasheet documentation #10040 available at: <https://www.bio-rad-antibodies.com/SDS/MCA519GT> 10040

---

**Regulatory** For research purposes only.

## Related Products

### Recommended Secondary Antibodies

|  |   |
|--|---|
| Rabbit Anti Rat IgG (STAR16...)                | <a href="#">DyLight®800</a>   |
| Rabbit Anti Rat IgG (STAR17...)                | <a href="#">FITC</a>  |
| Goat Anti Rat IgG (STAR69...)                  | <a href="#">FITC</a>  |
| Goat Anti Rat IgG (STAR73...)                  | <a href="#">RPE</a>   |
| Rabbit Anti Rat IgG (STAR21...)                | <a href="#">HRP</a>   |
| Goat Anti Rat IgG (MOUSE ADSORBED) (STAR71...) | <a href="#">DyLight®550</a> , <a href="#">DyLight®650</a> , <a href="#">DyLight®800</a> |
| Goat Anti Rat IgG (STAR131...)                 | <a href="#">Alk. Phos.</a> , <a href="#">Biotin</a>                                     |
| Goat Anti Rat IgG (STAR72...)                  | <a href="#">HRP</a>   |

**North & South America** Tel: +1 800 265 7376  
Fax: +1 919 878 3751

**Worldwide** Tel: +44 (0)1865 852 700  
Fax: +44 (0)1865 852 739

**Europe** Tel: +49 (0) 89 8090 95 21  
Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M404315:220822'

**Printed on 28 Aug 2024**

---